

SIGACHI LABORATORIES LIMITED  
REGD.OFFICE: S.No: 530 & 534, BONTHAPALLY - 502 313.  
JINNARAM MANDAL, MEDAK DISTRICT, TELANGANA

**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 30TH JUNE, 2015**

PART I		(Rs.in Lakhs)			
S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		(UN-AUDITED)	(UN-AUDITED)	(UN-AUDITED)	(AUDITED)
		30.06.2015	31.03.2015	30.06.2014	31.03.2015
1	Income from operations				
	(a) Net sales/income from operations (Net of excise duty)	14.00	27.50	13.00	79.50
	(b) Other operating income	8.42	8.87	9.05	33.73
	Total income from operations (net)	22.42	36.37	22.05	113.23
2	Expenses				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	(d) Employee benefit expenses	4.75	5.06	4.34	18.21
	(e) Depreciation and amortisation expenses	3.08	3.15	2.91	12.57
	(f) Other expenses	2.68	10.18	2.92	18.30
	Total expenses	10.51	18.39	10.17	49.08
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	11.91	17.98	11.88	64.15
4	Other income	1.35	4.09	2.32	19.96
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	13.26	22.07	14.20	84.11
6	Finance costs	0.01	0.04	0.01	0.09
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	13.25	22.03	14.19	84.02
8	Exceptional items	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7-8)	13.25	22.03	14.19	84.02
10	Tax Expense				
	a) Current Tax	3.00	7.00	2.00	19.50
	b) Prior period Tax	-	0.27	(1.01)	(0.74)
	c) Deferred Tax	1.00	3.73	-	5.98
	Total	4.00	11.00	0.99	24.74
11	Net Profit / (Loss) from ordinary activities after tax (9 - 10)	9.25	11.03	13.20	59.28
12	Extraordinary items (net of tax expense)	-	-	-	-
13	Net Profit / (Loss) for the period (11+/-12)	9.25	11.03	13.20	59.28
14	Paid-up equity share capital (Face Value of Rs.10/- per share)	675.31	675.31	675.31	675.31
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	234.94
16	Basic & Diluted Earnings per share before & after extraordinary items (not annualised) (Rs.)	0.14	0.16	0.20	0.88

**PART II**

A) PARTICULARS OF SHAREHOLDING					
1	Public Shareholding:				
	-Number of Shares	4387010	4387010	4367000	4387010
	-Percentage of Shareholding	64.96%	64.96%	64.67%	64.96%
2	Promoters and Promoter group Shareholding				
	a) Pledged / Encumbered				
	-Number of Shares	Nil	Nil	Nil	Nil
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
	-Percentage of Shares (as a % of the total share capital of the Company)	Nil	Nil	Nil	Nil
	b) Non - Encumbered				
	-Number of Shares	2366090	2366090	2386100	2366090
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	-Percentage of Shares (as a % of the total share capital of the Company)	35.04%	35.04%	35.33%	35.04%
B	Investor Complaints	Quarter ended 30.06.2015			
	Pending at the beginning of the quarter	NIL			
	Received during the quarter	0			
	Disposed of during the quarter	0			
	Remaining unresolved at the end of the quarter	NIL			

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

(Rs.in Lakhs)

PARTICULARS	QUARTER ENDED			YEAR
	(UN-AUDITED)	(UN-AUDITED)	(UN-AUDITED)	(AUDITED)
	30.06.2015	31.03.2015	30.06.2014	31.03.2015
Segment Revenue:				
a) Bulk Drugs and Intermediates	14.00	27.50	13.00	79.50
b) ICD's & FD's	8.42	8.87	9.05	33.73
c) Others	1.35	4.09	2.32	19.96
	<b>23.77</b>	<b>40.46</b>	<b>24.37</b>	<b>133.19</b>
Less: Inter Segment Revenue	-	-	-	-
Net Sales/Income from Operations	<b>23.77</b>	<b>40.46</b>	<b>24.37</b>	<b>133.19</b>
Segment Results:				
Profit/(Loss) before finance costs exceptional items and Tax				
a) Bulk Drugs and Intermediates	9.98	15.86	9.53	57.33
b) ICD's & FD's	8.42	8.87	9.05	33.73
c) Others	1.35	4.09	2.32	19.96
	<b>19.75</b>	<b>28.82</b>	<b>20.90</b>	<b>111.02</b>
Less:(i) Finance Costs	0.01	0.04	0.01	0.09
(ii) Other Unallocable Expenditure	6.49	6.75	6.70	26.91
Total Profit / (Loss) before Tax	<b>13.25</b>	<b>22.03</b>	<b>14.19</b>	<b>84.02</b>
Capital Employed:				
(Segment Assets - Liabilities)				
a) Bulk Drugs and Intermediates	359.73	436.58	328.35	436.58
b) ICD's & FD's	378.18	314.58	367.10	314.58
c) Others	237.34	214.84	224.47	214.84
	<b>975.25</b>	<b>966.00</b>	<b>919.92</b>	<b>966.00</b>

Notes:

1. The above results were reviewed by the audit committee and thereafter approved by the Board of Directors and taken on record at the respective meetings held on 13th August, 2015 and a Limited Review of the same has been carried out by the Statutory Auditors of the Com
2. Previous year figures have been regrouped / rearranged / reclassified to make them comparable with the current year figures, wherever necessary.

By Order of the Board  
for SIGACHI LABORATORIES LIMITED

Place: Hyderabad  
Date : 13-08-2015

Chairman & Managing Director

**SIGACHI LABORATORIES LIMITED**  
**REGD.OFFICE: S.No: 530 & 534, BONTHAPALLY - 502 313**  
**JINNARAM MANDAL,MEDAK DISTRICT, TELANGANA**

**STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH JUNE, 2015**

(Rs. in Lakhs)

S.NO.	PARTICULARS	As at 30.06.2015 (UnAudited)	As at 31.03.2015 (Audited)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>1. Shareholders' Funds</b>		
	(a) Share Capital	731.06	731.06
	(b) Reserves and Surplus	244.19	234.94
	<b>Sub-total - Shareholders' Funds</b>	<b>975.25</b>	<b>966.00</b>
	<b>2. Non-Current Liabilities</b>		
	(a) Other Long-term Liabilities	4.50	4.50
	(b) Long-term provisions	12.12	12.12
	<b>Sub-total - Non-Current Liabilities</b>	<b>16.62</b>	<b>16.62</b>
	<b>3. Current Liabilities</b>		
	(a) Short-term borrowings	-	-
	(b) Other Current Liabilities	11.72	14.12
	(c) Short-term Provisions	3.31	3.31
	<b>Sub-total - Current Liabilities</b>	15.03	17.43
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,006.90</b>	<b>1,000.05</b>
<b>B</b>	<b>ASSETS</b>		
	<b>1. Non-Current Assets</b>		
	(a) Fixed assets		
	(i) Tangible assets	260.04	263.12
	(ii) Intangible assets	-	-
	(b) Non-Current Investments	237.34	214.84
	(c) Deferred Tax Assets (Net)	16.90	17.90
	(d) Long-term Loans & Advances	97.94	94.87
	<b>Sub-total - Non-Current Assets</b>	<b>612.22</b>	<b>590.73</b>
	<b>2. Current Assets</b>		
	(a ) Trade Receivables	14.96	78.78
	(b) Cash and Cash equivalents	345.00	296.60
	(c) Short-term Loans & Advances	34.14	33.02
	(d) Other Current assets	0.58	0.92
	<b>Sub-total - Current Assets</b>	<b>394.68</b>	<b>409.32</b>
	<b>TOTAL ASSETS</b>	<b>1,006.90</b>	<b>1,000.05</b>

By Order of the Board  
for SIGACHI LABORATORIES LIMITED

Place : Hyderabad

Date : 13.08.2015

Chairman & Managing Director